 Aurinia Pharmaceuticals Inc NASDAQ: AUPH is up 4.8 to trade at 21.83, after a late-stage trial of the companys treatment for active lupus nephritis showed sustained efficacy and a favorable risk-benefit profile over a three-year period. 